Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study.
Mangioni D, Panigada M, Palomba E, Bobbio C, Chatenoud L, Alagna L, Fumagalli J, Gori A, Grancini A, Guzzardella A, Lombardi A, Matinato C, Meli A, Muscatello A, Porretti L, Tomasello M, Trombetta E, Valenti L, Bandera A, Grasselli G. Mangioni D, et al. Among authors: tomasello m. Crit Care. 2023 Sep 26;27(1):369. doi: 10.1186/s13054-023-04658-5. Crit Care. 2023. PMID: 37749631 Free PMC article.
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study.
Biscarini S, Villa S, Genovese C, Tomasello M, Tonizzo A, Fava M, Iannotti N, Bolis M, Mariani B, Valzano AG, Morlacchi LC, Donato F, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A, Lombardi A. Biscarini S, et al. Among authors: tomasello m. Biomedicines. 2022 Aug 18;10(8):2002. doi: 10.3390/biomedicines10082002. Biomedicines. 2022. PMID: 36009549 Free PMC article.
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, Tonizzo A, Fava M, Valzano AG, Morlacchi LC, Donato MF, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A. Lombardi A, et al. Among authors: tomasello m. Biomedicines. 2023 May 26;11(6):1540. doi: 10.3390/biomedicines11061540. Biomedicines. 2023. PMID: 37371635 Free PMC article.